Daiichi Sankyo has commenced a Phase I/II/III clinical trial of a booster dose of Covid-19 vaccine, DS-5670, in Japan.
The messenger ribonucleic acid (mRNA) vaccine leverages a new nucleic acid delivery technology.
In animal models, the vaccine elicited neutralising activities against the Omicron variant of the SARS-CoV-2 virus to some extent after the initial dosing.
Furthermore, the additional dose of the vaccine boosted neutralising activities, showing a possible booster effect.
The trial will assess the safety and efficacy of the booster vaccine in healthy Japanese adults, including elderly people, who completed the initial two-dose regimen with Covid-19 vaccines.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataSee Also:
Booster vaccine will be given a minimum of six months following the last vaccine dose.
The trial’s first part will decide the recommended booster dosage of the vaccine followed by a controlled trial that will enrol 4,500 adult subjects to assess DS-5670 against other vaccines in the country.
Daiichi Sankyo plans to develop and market the DS-5670 vaccine in Japan this year.
The vaccine’s clinical development is being carried out through Japan Agency for Medical Research and Development (AMED)-promoted “Vaccine development project” and “Urgent improvement project for vaccine manufacturing systems” supported by the Ministry of Health, Labour and Welfare.
In December last year, the company dosed the first subject in the Phase III DESTINY‑Breast11 clinical trial of Enhertu (trastuzumab deruxtecan) in patients with breast cancer.
This trial is intended to evaluate Enhertu as neoadjuvant therapy for high-risk human epidermal growth factor receptor 2 (HER2) positive early-stage breast cancer.
